Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma

Part of paid clinical trials in Tampa, Florida.

Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Study ID
NCT03834623
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • CC-122 — DRUG
    Oral CC-122 at 2 mg daily, 5 days out of 7
  • Nivolumab — DRUG
    240 mg Nivolumab intravenously days 1 and 15 in each 28 day cycle

Study Details

This study is to find out if the combination of CC-122 (an investigational agent) and Nivolumab will enhance the anti-cancer activity and prevent T-cell exhaustion (T-cells are responsible for maintaining the body's immune response).

Key Dates

Start date
May 14, 2019
Status verified
Sep 2022
Primary completion
Jun 29, 2021
Completion
Aug 4, 2021

Study Design

Enrollment
23 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: CC-122 Plus Nivolumab
    Participants will take CC-122 orally at 2mg daily for 5 consecutive days every 7 days, with intravenous nivolumab (240mg) in days 1 and 15 within a 28-day cycle.

Primary Outcome Measure

Objective Response Rate of CC-122 in Combination With Nivolumab [ Time Frame: Up to 52 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
H Lee Moffitt Cancer Center and Research InstituteTampaFlorida33612-

Find similar trials in Tampa, FL

By condition
Melanoma
By specialty
OncologySkin cancerDermatology
By research site
H Lee Moffitt Cancer Center and Research Institute· Tampa, FL

Related Studies